The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

“Patients treated with the venetoclax-obinutuzumab combination showed a statistically significant sustained prolongation of PFS compared with patients treated with chlorambucil-obinutuzumab (76. ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...